Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016


Sreih A. G. , Alibaz-Oner F., Kermani T. A. , Aydin S. Z. , Cronholm P. F. , Davis T., ...More

JOURNAL OF RHEUMATOLOGY, vol.44, no.12, pp.1933-1937, 2017 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 44 Issue: 12
  • Publication Date: 2017
  • Doi Number: 10.3899/jrheum.161467
  • Journal Name: JOURNAL OF RHEUMATOLOGY
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.1933-1937
  • Keywords: GIANT CELL ARTERITIS, TAKAYASU ARTERITIS, VASCULITIS, OUTCOME ASSESSMENT, GIANT-CELL ARTERITIS, QUALITY-OF-LIFE, ERYTHROCYTE SEDIMENTATION-RATE, C-REACTIVE PROTEIN, DOUBLE-BLIND TRIAL, TAKAYASU-ARTERITIS, ACTIVITY SCORE, DISEASE-ACTIVITY, POLYMYALGIA-RHEUMATICA, ABATACEPT CTLA-4IG

Abstract

Objective. Among the challenges in conducting clinical trials in large-vessel vasculitis (LVV), including both giant cell arteritis (GCA) and Takayasu arteritis (TA), is the lack of standardized and meaningful outcome measures. The Outcome Measures in Rheumatology (OMERACT) Vasculitis Working Group initiated an international effort to develop and validate data-driven outcome tools for clinical investigation in LVV.